Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 110 EP1388 | DOI: 10.1530/endoabs.110.EP1388

ECEESPE2025 ePoster Presentations Reproductive and Developmental Endocrinology (128 abstracts)

Clinical profile of turner syndrome patients in a tertiary endocrine center in Nepal

Ansumali Joshi 1 , Srijana Karmacharya 1 , Puspa Dahal 1 & Indu Rana 1


1Kathmandu Diabetes and Thyroid Center, Kathmandu, Nepal


JOINT1808

In Nepal, we have limited data regarding patients with Turner Syndrome, which is a rare chromosomal abnormality seen in females. We reviewed 16 cases of Turner Syndrome attending our endocrine center from July 2013 and Oct 2024. The mean age was 7.06 ± 5.82 (range 8 - 30) years, weight was 38.12 ± 13.42(range 18- 61) kg, height 131.21 cm ± 14.65 (range 104 - 153) cm and BMI was 20.96 ± 4.38 (range 16 - 30.4)kg/m2. All patients presented with shunted growth. Primary amenorrhea was seen in 8 patients (50%), secondary amenorrhea in 3 patients (18.75%), delayed puberty in 13 patients (81.25%). 2 patients were 8 years old and 1 patient 11 years old. Only one was married and she was infertile. Webbed neck feature was noted in 10 patients (62.5%) and low set ear in 5 patients (31.25%). Madelung deformity was found in 2 patients (12.5%), cubitus valgus 12 patients (75%), kyphosis in 1 patient (6.25%) and broad chest in 8(50%) patients. One patient (6.25%) had hearing impairment and one (6.25%) had ear infection. Left renal agenesis was seen in 1(6.25%). Hypothyroidism was present in 7 patients (43.75%), hyperthyroidism in 1 patient (6.25%) and lymphedema in 1 patient (6.25%). Diabetes was not present in our patients while 1 patient (6.25%) had hypertension. None of our patients had cardiac problems. Mean FSH at presentation was 83.65 mIU/ml. Karyotyping was 45X0 in 10 patients (62.5%) and Mosaic in 6 patients (37.5%). Ultrasonography showed hypoplastic uterus in all patients. Growth hormone treatment was done in 4(25%) patients for the duration ranging from 6 months to 2 years. Hormone replacement therapy was initiated with estrogen only in 8(50%) patients and a combined estrogen & progesterone sequential regime in 8 (50%) patients. All estrogen were conjugated estrogen and progesterone was Medroxyprogesterone acetate. Combined oral contraceptive (COC) was not used in our patients.

Volume 110

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

European Society of Endocrinology 
European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches